The below information is to inform you of a research
study about ovarian cancer maintenance therapy in Canada. This study is
conducted by Broadstreet HEOR on behalf of GlaxoSmithKline (also called “GSK”).
GSK is a company that discovers and makes vaccines, medicines, and other
healthcare products. Ovarian Cancer Canada is committed to driving research
forward, and therefore shares relevant research opportunities with those
affected by ovarian cancer, where appropriate.
If you have been diagnosed with ovarian cancer,
you may qualify
to take part in a 60-min
virtual interview about your experiences.
Broadstreet HEOR (a Canadian health research company) wants to speak with
adults with ovarian cancer who have received chemotherapy treatment in
Canada and were eligible for PARP inhibitor maintenance therapy afterward but
decided against taking it. Instead, you are being closely monitored by your
doctor and not on any active cancer drugs or treatments.
Anyone who qualifies
and participates will receive $80. All information and responses will
remain confidential.
To check if you’re eligible, email
Jessica Dunne at ovariancancerstudy@broadstreetheor.com.
